在活跃的RA中,对注射甲铁和甲铁片的疗效和安全性进行比较
Lin Qiao1,2,3,4, Jiankang Hu5, Daming Ou6
1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College.
Rheumatology (Oxford, England)
|February 7, 2025
概括
在治疗中国患者的活性类风湿性关节炎 (RA) 时,皮下注射甲状腺素 (SC MTX) 的疗效与口服甲状腺素 (OR MTX) 无差. 这两种治疗都被很好地容忍,SC MTX显示出潜在的更好的早期疗效和更少的胃肠道副作用.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,影响关节.
- 甲基 (MTX) 是 RA 的基石疗法.
- 对比皮下 (SC) 和口服 (OR) MTX 给药对于优化 RA 治疗至关重要.
研究的目的:
- 为了比较SC MTX与OR MTX在中国活跃RA患者中的疗效和安全性.
- 根据疾病活动得分-28 (DAS28-ESR) 和ACR标准来评估治疗反应.
- 评估两种注射途径的安全概况.
主要方法:
- 这是一项随机对照试验,涉及到活跃RA的中国患者.
- 患者被分配给接受SC MTX或OR MTX.
- 主要疗效终点是12周DAS28-ESR的变化.
主要成果:
- 在12周后,SC MTX和OR MTX都显著降低了DAS28-ESR得分.
- 发现SC MTX不低于OR MTX (组间差异: -0.173 ± 0.2041).
- 在最初的8周内,SC MTX在二级终点上显示出数量上更好的结果,以及胃肠道不良事件的发病率较低.
结论:
- 在活跃的RA患者中,SC MTX的整体治疗效果与OR MTX相当.
- 一般来说,SC MTX的耐受性很好,其安全性与OR MTX相似.
- SC MTX可能会提供更快的初始症状改善和更好的胃肠道安全概况.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:16Bioequivalence: Overview
912
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
912
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
94
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
94